Lisa Pleyer

Research output

Research output per year 2004 2010 2015 2017 2018 2024

• 40 Original Article
• 19 Abstract (Journal)
• 13 Chapter
• 10 Review article
• 8 More
  • 5 Case report
  • 1 Short comment / notes
  • 1 Correction
  • 1 Editorial

Research output per year

Research output per year

Search results

• 2022

  Cox Proportional Hazards Deep Neural Network Identifies Peripheral Blood Complete Remission (PB-CR) to be at Least Equivalent to Morphologic CR in Predicting Outcomes of Patients Treated with Azacitidine - a Prospective Cohort Study By the AGMT

  Pleyer, L., Vaisband, M., Pfeilstocker, M., Stauder, R., Heibl, S., Sill, H., Girschikofsky, M., Stampfl-Mattersberger, M., Tinchon, C., Hartmann, B., Petzer, A., Schreder, M., Schmitt, C., Vallet, S., Melchardt, T., Scagnetti, L., Zebisch, A., Machherndl-Spandl, S., Wolf, D. & Keil, F. & 2 others, Hasenauer, J. & Greil, R., 2022, In: BLOOD . 140, p. 1346-1349

  Research output: Contribution to journal › Abstract (Journal) › peer-review

• Subclonal KIT D816V Mutations Are Prevalent in Chronic Myelomonocytic Leukemia and Correlate with Distinct Phenotypic Features

  Hunter, A., Newman, H., Solary, E., Geissler, K., Palomo, L., Zamora, L., Sole, F., Santini, V., Graubert, T., Thota, S., Griffiths, E., Pleyer, L., Thol, F., Bejar, R., Aguirre, L., Sallman, D., Kuykendall, A., Komrokji, R., George, T. & Padron, E., 2022, In: BLOOD . 140, p. 9824-9827

  Research output: Contribution to journal › Abstract (Journal) › peer-review
• 2021

  Peripheral Blood Complete Remission Provides Added Value to the Classical Definition of Morphologic Complete Remission - a Prospective Cohort Study of 1441 Patients with MDS, CMML and AML Treated within the Austrian Azacitidine Registry

  Pleyer, L., Pfeilstocker, M., Stauder, R., Heibl, S., Sill, H., Girschikofsky, M., Stampfl-Mattesberger, M., Tinchon, C., Hartmann, B., Petzer, A., Petricevic, B., Schmitt, C., Vallet, S., Geissler, K., Sperr, W., Leisch, M., Egle, A., Melchardt, T., Piringer, G. & Zebisch, A. & 7 others, Machherndl-Spandl, S., Wolf, D., Keil, F., Angermann, H., Drost, M., Larcher-Senn, J. & Greil, R., 2021, In: BLOOD . 138

  Research output: Contribution to journal › Abstract (Journal) › peer-review
  3 Citations (Web of Science)

• The EQ-5D-5L Predicts Treatment Outcomes and Provides Added Value to the R-IPSS in Patients with MDS, CMML or AML Treated within the Austrian Azacitidine Registry - a Prospective Cohort Study By the AGMT Study Group

  Pleyer, L., Heibl, S., Tinchon, C., Vallet, S., Petricevic, B., Leisch, M., Egle, A., Senn, T., Grochtdreis, T., Greil, R. & Stauder, R., 2021, In: BLOOD . 138

  Research output: Contribution to journal › Abstract (Journal) › peer-review
• 2019

  Treatment with 5-Azacytidine results in expression of long terminal repeat (LTR) elements in peripheral blood mononuclear cells of patients with MDS and AML: first pilot study

  Daskalakis, M., Haubitz, M., Steiner, D., Helf, M., Brocks, D., Pleyer, L., Greil, R., Plass, C., Baerlocher, G. & Leibundgut, E., 2019, In: SWISS MEDICAL WEEKLY. 149, p. 22S-22S

  Research output: Contribution to journal › Abstract (Journal) › peer-review
• 2017

  EVALUATION OF SALVAGE INDUCTION CHEMOTHERAPY REGIMENS IN MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA AFTER HYPOMETHYLATING AGENT TREATMENT FAILURE

  Ball, B., Komrokji, R., Ades, L., Sekeres, M., DeZern, A., Pleyer, L., Vey, N., Almeida, A., Germing, U., Cluzeau, T., Platzbecker, U., Gore, S., Fenaux, P. & Prebet, T., 2017, In: LEUKEMIA RESEARCH . 55, p. S58-S59

  Research output: Contribution to journal › Abstract (Journal) › peer-review

• NGS ANALYSIS OF 474 BONE MARROW SAMPLES FROM 157 AML PATIENTS TREATED WITH AZACITIDINE-IMPACT OF AGE ON MUTATIONAL LOAD

  Pleyer, L., Gassner, F. J., Burgstaller, S., Wedler, H., Hartmann, T., Jansko, B., Neureiter, D., Thaler, J. & Greil, R., 2017, In: HAEMATOLOGICA . 102, p. 215-216

  Research output: Contribution to journal › Abstract (Journal) › peer-review
• 2015

  Azacitidine in Older Patients with Acute Myeloid Leukemia (AML). Results from the Expanded International E-Alma Series (E-ALMA plus ) According to the MRC Risk Index Score

  Falantes, J., Thepot, S., Pleyer, L., Maurillo, L., Martinez-Robles, V., Itzykson, R., Bargay, J., Stauder, R., Venditti, A., Martinez, M., Seegers, V., Foncillas, M., Burgstaller, S., Gardin, C., Montesinos, P., Musto, P., Greil, R., Sanz, M., Fenaux, P. & Ramos, F., 2015, In: BLOOD . 126, 23

  Research output: Contribution to journal › Abstract (Journal) › peer-review

• CLINICAL OUTCOMES OF ACUTE ERYTHROLEUKEMIA TREATED WITH AZACITIDINE: A RETROSPECTIVE MULTICENTER STUDY

  Almeida, A., Prebet, T., Itzykson, R., Ramos, F., Al Ali, H., Shammo, J., Pinto, R., Maurillo, L., WetzeI, J., Musto, P., van de Loosdrecht, A., Costa, M., Burgstaller, S., Stauder, R., Auzinger, G., Lang, A., Krippl, P., Geissler, D., Falantes, J. & Pedro, C. & 11 others, Bargay, J., Deben, G., Garrido, A., Bonanad, S., Diez-Campelo, M., Fenaux, P., Thepot, S., Ades, L., Sekeres, M., Greil, R. & Pleyer, L., 2015, In: HAEMATOLOGICA . 100, p. 384-384

  Research output: Contribution to journal › Abstract (Journal) › peer-review

• Is It Time to Redefine Response in Elderly Patients with WHO-Acute Myeloid Leukemia (AML) Unfit for Intensive Chemotherapy?

  Pleyer, L., Burgstaller, S., Stauder, R., Girschikofsky, M., Sill, H., Schlick, K., Thaler, J., Halter, B., Machherndl-Spandl, S., Zebisch, A., Pichler, A., Pfeilstocker, M., Autzinger, E., Lang, A., Geissler, K., Voskova, D., Geissler, D., Sperr, W., Hojas, S. & Rogulj, I. & 2 others, Andel, J. & Greil, R., 2015, In: BLOOD . 126, 23

  Research output: Contribution to journal › Abstract (Journal) › peer-review

• MRD dynamics after chemoimmunotherapy induction treatment of CLL independently predict outcome: first analysis of a secondary endpoint from the international randomized AGMT-CLL8/a Mabtenance trial

  Egle, A., Doubek, M., Stehlikova, O., Pleyer, L., Altenhofer, P., Melchardt, T., Smolej, L., Mihaylov, G., Mikuskova, E., Mayer, J. & Greil, R., 2015, In: LEUKEMIA & LYMPHOMA . 56, p. 123-124

  Research output: Contribution to journal › Abstract (Journal) › peer-review
• 2014

  Azacitidine in Acute Myeloid Leukemia: Comparison of Patients with AML-MRF Vs AML-NOS Enrolled in the Austrian Azacitidine Registry

  Pleyer, L., Burgstaller, S., Stauder, R., Girschikofsky, M., Linkesch, W., Pfeilstocker, M., Autzinger, E., Tinchon, C., Sliwa, T., Lang, A., Sperr, W., Geissler, D., Krippl, P., Voskova, D., Rossmann, D., Schlick, K., Thaler, J., Halter, B., Machherndl-Spandl, S. & Theiler, G. & 3 others, Valent, P., Eckmullner, O. & Greil, R., 2014, In: BLOOD . 124, 21

  Research output: Contribution to journal › Abstract (Journal) › peer-review
• 2012

  Complications of 5-azacytidine: Three cases of severe colitis in a single center cohort

  Melchardt, T., Weiss, L., Pleyer, L., Steinkirchner, S., Greil, R. & Egle, A., 2012, In: ONKOLOGIE . 35, p. 149-149

  Research output: Contribution to journal › Abstract (Journal) › peer-review
• 2011

  Activity of Azacitidine in 26 Unselected, Consecutive CMML Patients Included in the Austrian Azacitidine Registry (AAR) of the AGMT-Study Group

  Pleyer, L., Stauder, R., Burgstaller, S., Schreder, M., Tinchon, C., Pfeilstocker, M., Steinkirchner, S., Melchardt, T., Mitrovic, M., Girschikofsky, M., Lang, A., Krippl, P., Egle, A., Sliwa, T., Linkesch, W., Fridrik, M. & Greil, R., 2011, In: BLOOD . 118, 21, p. 747-747

  Research output: Contribution to journal › Abstract (Journal) › peer-review

  1 Citation (Web of Science)
• 2010

  HETEROGENEOUS EXPRESSION PATTERN OF HEDGEHOG SIGNALLING PATHWAY IN HEMATOPOIESIS OF MYELODYSPLASTIC SYNDROME

  Neureiter, D., Kemmerling, R., Alinger, B., Kiesslich, T., Faber, V., Stocher, M., Pleyer, L., Greil, R. & Dietz, O., 2010, In: HAEMATOLOGICA . 95, p. 375-375

  Research output: Contribution to journal › Abstract (Journal) › peer-review
• 2009

  FINAL RESULTS OF ORAL FLUDARABINE WITH CONCOMITANT SUBCUTANEOUS ALEMTUZUMAB IN RELAPSED/REFRACTORY B-CHRONIC LYMPHOCYTIC LEUKAEMIA (B-CLL): THE FLUSALEM STUDY

  Egle, A., Melchardt, T., Pleyer, L., Tinhofer, I., Lang, A., Keil, F., Thaler, J., Gunsilius, E., Fridrik, M. & Greil, R., 2009, In: HAEMATOLOGICA . 94, p. 140-140

  Research output: Contribution to journal › Abstract (Journal) › peer-review
• 2008

  Minimal Residual Disease (MRD) and T/NK Cell Dynamics during Fludarabine, Cyclophosphamide Plus Rituximab (FCR) Followed by Fludarabine Plus Rituximab (FR) and Remission Maintenance Therapy with Rituximab in Previously Untreated B-Chronic Lymphocytic Leukemia (B-CLL): Riskfactor Stratification in the Chairos Study.

  Egle, A., Weiss, L., Gassner, F. J., Russ, G., Pleyer, L., Gunsilius, E., Tinhofer, I., Thaler, J., Petzer, A. & Greil, R., 2008, In: BLOOD . 112, 11, p. 1089-1089

  Research output: Contribution to journal › Abstract (Journal) › peer-review

  1 Citation (Web of Science)
• 2007

  Planned first efficacy and safety analysis of de-intensified induction with fludarabine, cyclophosphamide plus rituximab (FCR) followed by fludarabine plus rituximab (FR) and remission maintenance therapy with rituximab in previously untreated B-chronic lymphocytic leukemia (B-CLL): The chairos study

  Egle, A., Weiss, L., Russ, G., Thoedtmann, R., Pleyer, L., Gastl, G., Thaler, J., Petzer, A., Tinhofer, I. & Greil, R., 2007, In: BLOOD . 110, 11, p. 609A-609A

  Research output: Contribution to journal › Abstract (Journal) › peer-review

  1 Citation (Web of Science)
• 2004

  Attenuation of virulence properties of Candida albicans in vitro by basidiomycete metabolites

  Pleyer, L., Ressler, S., Berg, A., Wurzner, R. & Dierich, M., 2004, In: INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY . 294, p. 192-192

  Research output: Contribution to journal › Abstract (Journal) › peer-review